Industry Research Reports
Global Omalizumab Biosimilars Market Research Report 2026
Industry: Pharma & Healthcare
Published Date: 2026-04-16
Pages: 120 Pages
Report ld: 6388711
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Omalizumab Biosimilars Market Size(US$)
CAGR 2026-2032
11.2%
Market Size,2032
USD 598
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 315 million
Market Forecast in 2032(Value)
US$ 598 million
CAGR
11.2%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Omalizumab Biosimilars competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
In 2025, global Omalizumab Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
This report delivers a comprehensive overview of the global Omalizumab Biosimilars market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Omalizumab Biosimilars. The Omalizumab Biosimilars market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Omalizumab Biosimilars market comprehensively. Regional market sizes by Type, by Application, by Age, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Omalizumab Biosimilars manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
MARKET SEGMENTATION
By Company
- Roche
- Novartis
- Glenmark Pharmaceuticals
- Selexis
- Generium
- CuraTeQ
- Celltrion Healthcare
- Alvotech
- BiosanaPharma
- Mabpharm
- CSPC Pharmaceutical Group
- Biomabs
- HisunPharm
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- 150 mg/mL
- 75 mg/0.5 mL
Segment by Application
- Persistent Asthma
- Nasal Polyps
- Chronic Idiopathic Urticaria
Segment by Category
- For Adults
- For Teenagers
- For Children
Segment by Division
- Every 2 Weeks
- Every 4 Weeks
- Individualized Dosing Regimen
CHAPTER OUTLINE
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Age, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Omalizumab Biosimilars manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Omalizumab Biosimilars sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Omalizumab Biosimilars Market Overview
1.1 Product Definition
1.2 Omalizumab Biosimilars by Type
1.2.1 Global Omalizumab Biosimilars Market Value by Type: 2025 vs 2032
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Omalizumab Biosimilars by Age
1.3.1 Global Omalizumab Biosimilars Market Value by Age: 2025 vs 2032
1.3.2 For Adults
1.3.3 For Teenagers
1.3.4 For Children
1.4 Omalizumab Biosimilars by Frequency
1.4.1 Global Omalizumab Biosimilars Market Value by Frequency: 2025 vs 2032
1.4.2 Every 2 Weeks
1.4.3 Every 4 Weeks
1.4.4 Individualized Dosing Regimen
1.5 Omalizumab Biosimilars by Application
1.5.1 Global Omalizumab Biosimilars Market Value by Application: 2025 vs 2032
1.5.2 Persistent Asthma
1.5.3 Nasal Polyps
1.5.4 Chronic Idiopathic Urticaria
1.6 Global Omalizumab Biosimilars Market Size Estimates and Forecasts
1.6.1 Global Omalizumab Biosimilars Revenue 2021–2032
1.6.2 Global Omalizumab Biosimilars Sales 2021–2032
1.6.3 Global Omalizumab Biosimilars Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Omalizumab Biosimilars Market Competition by Manufacturers
2.1 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2021–2026)
2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Omalizumab Biosimilars Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Omalizumab Biosimilars, Product Types and Applications
2.7 Global Key Manufacturers of Omalizumab Biosimilars, Date of Entry into the Industry
2.8 Global Omalizumab Biosimilars Market Competitive Situation and Trends
2.8.1 Global Omalizumab Biosimilars Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Omalizumab Biosimilars Players Market Share by Revenue
2.8.3 Global Omalizumab Biosimilars Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Omalizumab Biosimilars Market Scenario by Region
3.1 Global Omalizumab Biosimilars Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Omalizumab Biosimilars Sales by Region: 2021–2032
3.2.1 Global Omalizumab Biosimilars Sales by Region: 2021–2026
3.2.2 Global Omalizumab Biosimilars Sales by Region: 2027–2032
3.3 Global Omalizumab Biosimilars Revenue by Region: 2021–2032
3.3.1 Global Omalizumab Biosimilars Revenue by Region: 2021–2026
3.3.2 Global Omalizumab Biosimilars Revenue by Region: 2027–2032
3.4 North America Omalizumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Omalizumab Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Omalizumab Biosimilars Sales by Country (2021–2032)
3.4.3 North America Omalizumab Biosimilars Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Omalizumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Omalizumab Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Omalizumab Biosimilars Sales by Country (2021–2032)
3.5.3 Europe Omalizumab Biosimilars Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Omalizumab Biosimilars Market Facts & Figures by Region
3.6.1 Asia Pacific Omalizumab Biosimilars Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Omalizumab Biosimilars Sales by Region (2021–2032)
3.6.3 Asia Pacific Omalizumab Biosimilars Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Omalizumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Omalizumab Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Omalizumab Biosimilars Sales by Country (2021–2032)
3.7.3 Latin America Omalizumab Biosimilars Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Omalizumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Omalizumab Biosimilars Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Omalizumab Biosimilars Sales by Country (2021–2032)
3.8.3 Middle East and Africa Omalizumab Biosimilars Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Omalizumab Biosimilars Sales by Type (2021–2032)
4.1.1 Global Omalizumab Biosimilars Sales by Type (2021–2026)
4.1.2 Global Omalizumab Biosimilars Sales by Type (2027–2032)
4.1.3 Global Omalizumab Biosimilars Sales Market Share by Type (2021–2032)
4.2 Global Omalizumab Biosimilars Revenue by Type (2021–2032)
4.2.1 Global Omalizumab Biosimilars Revenue by Type (2021–2026)
4.2.2 Global Omalizumab Biosimilars Revenue by Type (2027–2032)
4.2.3 Global Omalizumab Biosimilars Revenue Market Share by Type (2021–2032)
4.3 Global Omalizumab Biosimilars Price by Type (2021–2032)
5 Segment by Application
5.1 Global Omalizumab Biosimilars Sales by Application (2021–2032)
5.1.1 Global Omalizumab Biosimilars Sales by Application (2021–2026)
5.1.2 Global Omalizumab Biosimilars Sales by Application (2027–2032)
5.1.3 Global Omalizumab Biosimilars Sales Market Share by Application (2021–2032)
5.2 Global Omalizumab Biosimilars Revenue by Application (2021–2032)
5.2.1 Global Omalizumab Biosimilars Revenue by Application (2021–2026)
5.2.2 Global Omalizumab Biosimilars Revenue by Application (2027–2032)
5.2.3 Global Omalizumab Biosimilars Revenue Market Share by Application (2021–2032)
5.3 Global Omalizumab Biosimilars Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Omalizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Omalizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Glenmark Pharmaceuticals
6.3.1 Glenmark Pharmaceuticals Company Information
6.3.2 Glenmark Pharmaceuticals Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Portfolio
6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.4 Selexis
6.4.1 Selexis Company Information
6.4.2 Selexis Description and Business Overview
6.4.3 Selexis Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Selexis Omalizumab Biosimilars Product Portfolio
6.4.5 Selexis Recent Developments/Updates
6.5 Generium
6.5.1 Generium Company Information
6.5.2 Generium Description and Business Overview
6.5.3 Generium Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Generium Omalizumab Biosimilars Product Portfolio
6.5.5 Generium Recent Developments/Updates
6.6 CuraTeQ
6.6.1 CuraTeQ Company Information
6.6.2 CuraTeQ Description and Business Overview
6.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 CuraTeQ Omalizumab Biosimilars Product Portfolio
6.6.5 CuraTeQ Recent Developments/Updates
6.7 Celltrion Healthcare
6.7.1 Celltrion Healthcare Company Information
6.7.2 Celltrion Healthcare Description and Business Overview
6.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Portfolio
6.7.5 Celltrion Healthcare Recent Developments/Updates
6.8 Alvotech
6.8.1 Alvotech Company Information
6.8.2 Alvotech Description and Business Overview
6.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Alvotech Omalizumab Biosimilars Product Portfolio
6.8.5 Alvotech Recent Developments/Updates
6.9 BiosanaPharma
6.9.1 BiosanaPharma Company Information
6.9.2 BiosanaPharma Description and Business Overview
6.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 BiosanaPharma Omalizumab Biosimilars Product Portfolio
6.9.5 BiosanaPharma Recent Developments/Updates
6.10 Mabpharm
6.10.1 Mabpharm Company Information
6.10.2 Mabpharm Description and Business Overview
6.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Mabpharm Omalizumab Biosimilars Product Portfolio
6.10.5 Mabpharm Recent Developments/Updates
6.11 CSPC Pharmaceutical Group
6.11.1 CSPC Pharmaceutical Group Company Information
6.11.2 CSPC Pharmaceutical Group Description and Business Overview
6.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Portfolio
6.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.12 Biomabs
6.12.1 Biomabs Company Information
6.12.2 Biomabs Description and Business Overview
6.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Biomabs Omalizumab Biosimilars Product Portfolio
6.12.5 Biomabs Recent Developments/Updates
6.13 HisunPharm
6.13.1 HisunPharm Company Information
6.13.2 HisunPharm Description and Business Overview
6.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 HisunPharm Omalizumab Biosimilars Product Portfolio
6.13.5 HisunPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Omalizumab Biosimilars Industry Chain Analysis
7.2 Omalizumab Biosimilars Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Omalizumab Biosimilars Production Mode & Process Analysis
7.4 Omalizumab Biosimilars Sales and Marketing
7.4.1 Omalizumab Biosimilars Sales Channels
7.4.2 Omalizumab Biosimilars Distributors
7.5 Omalizumab Biosimilars Customer Analysis
8 Omalizumab Biosimilars Market Dynamics
8.1 Omalizumab Biosimilars Industry Trends
8.2 Omalizumab Biosimilars Market Drivers
8.3 Omalizumab Biosimilars Market Challenges
8.4 Omalizumab Biosimilars Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Omalizumab Biosimilars Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Omalizumab Biosimilars Market Value by Age (US$ Million), 2025 vs 2032
Table 3. Global Omalizumab Biosimilars Market Value by Frequency (US$ Million), 2025 vs 2032
Table 4. Global Omalizumab Biosimilars Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Omalizumab Biosimilars Market Competitive Situation by Manufacturers in 2025
Table 6. Global Omalizumab Biosimilars Sales (K Dose) of Key Manufacturers (2021–2026)
Table 7. Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Omalizumab Biosimilars Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Omalizumab Biosimilars Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Omalizumab Biosimilars Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Omalizumab Biosimilars, Product Types and Applications
Table 14. Global Key Manufacturers of Omalizumab Biosimilars, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Omalizumab Biosimilars Companies by Tier (Tier 1, Tier 2, Tier 3), based on Omalizumab Biosimilars Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Omalizumab Biosimilars Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Omalizumab Biosimilars Sales by Region (K Dose), 2021–2026
Table 20. Global Omalizumab Biosimilars Sales Market Share by Region (2021–2026)
Table 21. Global Omalizumab Biosimilars Sales by Region (K Dose), 2027–2032
Table 22. Global Omalizumab Biosimilars Sales Market Share by Region (2027–2032)
Table 23. Global Omalizumab Biosimilars Revenue by Region (US$ Million), 2021–2026
Table 24. Global Omalizumab Biosimilars Revenue Market Share by Region (2021–2026)
Table 25. Global Omalizumab Biosimilars Revenue by Region (US$ Million), 2027–2032
Table 26. Global Omalizumab Biosimilars Revenue Market Share by Region (2027–2032)
Table 27. North America Omalizumab Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Omalizumab Biosimilars Sales by Country (K Dose), 2021–2026
Table 29. North America Omalizumab Biosimilars Sales by Country (K Dose), 2027–2032
Table 30. North America Omalizumab Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 31. North America Omalizumab Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Omalizumab Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Omalizumab Biosimilars Sales by Country (K Dose), 2021–2026
Table 34. Europe Omalizumab Biosimilars Sales by Country (K Dose), 2027–2032
Table 35. Europe Omalizumab Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Omalizumab Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Omalizumab Biosimilars Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Omalizumab Biosimilars Sales by Region (K Dose), 2021–2026
Table 39. Asia Pacific Omalizumab Biosimilars Sales by Region (K Dose), 2027–2032
Table 40. Asia Pacific Omalizumab Biosimilars Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Omalizumab Biosimilars Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Omalizumab Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Omalizumab Biosimilars Sales by Country (K Dose), 2021–2026
Table 44. Latin America Omalizumab Biosimilars Sales by Country (K Dose), 2027–2032
Table 45. Latin America Omalizumab Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Omalizumab Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Omalizumab Biosimilars Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Omalizumab Biosimilars Sales by Country (K Dose), 2021–2026
Table 49. Middle East and Africa Omalizumab Biosimilars Sales by Country (K Dose), 2027–2032
Table 50. Middle East and Africa Omalizumab Biosimilars Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Omalizumab Biosimilars Revenue by Country (US$ Million), 2027–2032
Table 52. Global Omalizumab Biosimilars Sales (K Dose) by Type (2021–2026)
Table 53. Global Omalizumab Biosimilars Sales (K Dose) by Type (2027–2032)
Table 54. Global Omalizumab Biosimilars Sales Market Share by Type (2021–2026)
Table 55. Global Omalizumab Biosimilars Sales Market Share by Type (2027–2032)
Table 56. Global Omalizumab Biosimilars Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Omalizumab Biosimilars Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Omalizumab Biosimilars Revenue Market Share by Type (2021–2026)
Table 59. Global Omalizumab Biosimilars Revenue Market Share by Type (2027–2032)
Table 60. Global Omalizumab Biosimilars Price (US$/Dose) by Type (2021–2026)
Table 61. Global Omalizumab Biosimilars Price (US$/Dose) by Type (2027–2032)
Table 62. Global Omalizumab Biosimilars Sales (K Dose) by Application (2021–2026)
Table 63. Global Omalizumab Biosimilars Sales (K Dose) by Application (2027–2032)
Table 64. Global Omalizumab Biosimilars Sales Market Share by Application (2021–2026)
Table 65. Global Omalizumab Biosimilars Sales Market Share by Application (2027–2032)
Table 66. Global Omalizumab Biosimilars Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Omalizumab Biosimilars Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Omalizumab Biosimilars Revenue Market Share by Application (2021–2026)
Table 69. Global Omalizumab Biosimilars Revenue Market Share by Application (2027–2032)
Table 70. Global Omalizumab Biosimilars Price (US$/Dose) by Application (2021–2026)
Table 71. Global Omalizumab Biosimilars Price (US$/Dose) by Application (2027–2032)
Table 72. Roche Company Information
Table 73. Roche Description and Business Overview
Table 74. Roche Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 75. Roche Omalizumab Biosimilars Product
Table 76. Roche Recent Developments/Updates
Table 77. Novartis Company Information
Table 78. Novartis Description and Business Overview
Table 79. Novartis Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 80. Novartis Omalizumab Biosimilars Product
Table 81. Novartis Recent Developments/Updates
Table 82. Glenmark Pharmaceuticals Company Information
Table 83. Glenmark Pharmaceuticals Description and Business Overview
Table 84. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 85. Glenmark Pharmaceuticals Omalizumab Biosimilars Product
Table 86. Glenmark Pharmaceuticals Recent Developments/Updates
Table 87. Selexis Company Information
Table 88. Selexis Description and Business Overview
Table 89. Selexis Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 90. Selexis Omalizumab Biosimilars Product
Table 91. Selexis Recent Developments/Updates
Table 92. Generium Company Information
Table 93. Generium Description and Business Overview
Table 94. Generium Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 95. Generium Omalizumab Biosimilars Product
Table 96. Generium Recent Developments/Updates
Table 97. CuraTeQ Company Information
Table 98. CuraTeQ Description and Business Overview
Table 99. CuraTeQ Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 100. CuraTeQ Omalizumab Biosimilars Product
Table 101. CuraTeQ Recent Developments/Updates
Table 102. Celltrion Healthcare Company Information
Table 103. Celltrion Healthcare Description and Business Overview
Table 104. Celltrion Healthcare Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 105. Celltrion Healthcare Omalizumab Biosimilars Product
Table 106. Celltrion Healthcare Recent Developments/Updates
Table 107. Alvotech Company Information
Table 108. Alvotech Description and Business Overview
Table 109. Alvotech Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 110. Alvotech Omalizumab Biosimilars Product
Table 111. Alvotech Recent Developments/Updates
Table 112. BiosanaPharma Company Information
Table 113. BiosanaPharma Description and Business Overview
Table 114. BiosanaPharma Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 115. BiosanaPharma Omalizumab Biosimilars Product
Table 116. BiosanaPharma Recent Developments/Updates
Table 117. Mabpharm Company Information
Table 118. Mabpharm Description and Business Overview
Table 119. Mabpharm Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 120. Mabpharm Omalizumab Biosimilars Product
Table 121. Mabpharm Recent Developments/Updates
Table 122. CSPC Pharmaceutical Group Company Information
Table 123. CSPC Pharmaceutical Group Description and Business Overview
Table 124. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 125. CSPC Pharmaceutical Group Omalizumab Biosimilars Product
Table 126. CSPC Pharmaceutical Group Recent Developments/Updates
Table 127. Biomabs Company Information
Table 128. Biomabs Description and Business Overview
Table 129. Biomabs Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 130. Biomabs Omalizumab Biosimilars Product
Table 131. Biomabs Recent Developments/Updates
Table 132. HisunPharm Company Information
Table 133. HisunPharm Description and Business Overview
Table 134. HisunPharm Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 135. HisunPharm Omalizumab Biosimilars Product
Table 136. HisunPharm Recent Developments/Updates
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Omalizumab Biosimilars Distributors List
Table 140. Omalizumab Biosimilars Customers List
Table 141. Omalizumab Biosimilars Market Trends
Table 142. Omalizumab Biosimilars Market Drivers
Table 143. Omalizumab Biosimilars Market Challenges
Table 144. Omalizumab Biosimilars Market Restraints
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
Table 148. Authors List of This Report
List of Figures
Figure 1. Product Picture of Omalizumab Biosimilars
Figure 2. Global Omalizumab Biosimilars Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Omalizumab Biosimilars Market Share by Type: 2025 & 2032
Figure 4. 150 mg/mL Product Picture
Figure 5. 75 mg/0.5 mL Product Picture
Figure 6. Global Omalizumab Biosimilars Market Value by Age (US$ Million), 2021–2032
Figure 7. Global Omalizumab Biosimilars Market Share by Age: 2025 vs 2032
Figure 8. For Adults Product Picture
Figure 9. For Teenagers Product Picture
Figure 10. For Children Product Picture
Figure 11. Global Omalizumab Biosimilars Market Value by Frequency (US$ Million), 2021–2032
Figure 12. Global Omalizumab Biosimilars Market Share by Frequency: 2025 vs 2032
Figure 13. Every 2 Weeks Product Picture
Figure 14. Every 4 Weeks Product Picture
Figure 15. Individualized Dosing Regimen Product Picture
Figure 16. Global Omalizumab Biosimilars Market Value by Application (US$ Million), 2021–2032
Figure 17. Global Omalizumab Biosimilars Market Share by Application: 2025 & 2032
Figure 18. Persistent Asthma
Figure 19. Nasal Polyps
Figure 20. Chronic Idiopathic Urticaria
Figure 21. Global Omalizumab Biosimilars Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Omalizumab Biosimilars Market Size (US$ Million), 2021–2032
Figure 23. Global Omalizumab Biosimilars Sales (K Dose), 2021–2032
Figure 24. Global Omalizumab Biosimilars Average Price (US$/Dose), 2021–2032
Figure 25. Omalizumab Biosimilars Report Years Considered
Figure 26. Omalizumab Biosimilars Sales Share by Manufacturers in 2025
Figure 27. Global Omalizumab Biosimilars Revenue Share by Manufacturers in 2025
Figure 28. Top 5 and Top 10 Global Omalizumab Biosimilars Players: Market Share by Revenue in Omalizumab Biosimilars in 2025
Figure 29. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 30. Global Omalizumab Biosimilars Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 31. North America Omalizumab Biosimilars Sales Market Share by Country (2021–2032)
Figure 32. North America Omalizumab Biosimilars Revenue Market Share by Country (2021–2032)
Figure 33. U.S. Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Canada Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Europe Omalizumab Biosimilars Sales Market Share by Country (2021–2032)
Figure 36. Europe Omalizumab Biosimilars Revenue Market Share by Country (2021–2032)
Figure 37. Germany Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. France Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. U.K. Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Italy Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Russia Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Asia Pacific Omalizumab Biosimilars Sales Market Share by Region (2021–2032)
Figure 43. Asia Pacific Omalizumab Biosimilars Revenue Market Share by Region (2021–2032)
Figure 44. China Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Japan Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. South Korea Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. India Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Australia Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Taiwan Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Indonesia Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Thailand Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Malaysia Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Philippines Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Latin America Omalizumab Biosimilars Sales Market Share by Country (2021–2032)
Figure 55. Latin America Omalizumab Biosimilars Revenue Market Share by Country (2021–2032)
Figure 56. Mexico Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Brazil Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Argentina Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Middle East and Africa Omalizumab Biosimilars Sales Market Share by Country (2021–2032)
Figure 60. Middle East and Africa Omalizumab Biosimilars Revenue Market Share by Country (2021–2032)
Figure 61. Turkey Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Saudi Arabia Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 63. U.A.E Omalizumab Biosimilars Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Global Sales Market Share of Omalizumab Biosimilars by Type (2021–2032)
Figure 65. Global Revenue Market Share of Omalizumab Biosimilars by Type (2021–2032)
Figure 66. Global Omalizumab Biosimilars Price (US$/Dose) by Type (2021–2032)
Figure 67. Global Sales Market Share of Omalizumab Biosimilars by Application (2021–2032)
Figure 68. Global Revenue Market Share of Omalizumab Biosimilars by Application (2021–2032)
Figure 69. Global Omalizumab Biosimilars Price (US$/Dose) by Application (2021–2032)
Figure 70. Omalizumab Biosimilars Value Chain
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 11.2% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
Which companies rank high in the global Omalizumab Biosimilars market?
What was the global market size of Omalizumab Biosimilars in 2026?
What was the global market size of Omalizumab Biosimilars in 2032?
What is the annual compound growth rate of the global Omalizumab Biosimilars market size from 2026 to 2032?
Related Reports
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 139
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-04-16
Pages: 164
USD 4900.00
(Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published Date: 2026-04-16
Pages: 142
USD 4250.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 119
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 90
USD 2900.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-20
Pages: 90
USD 2900.00
(Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-11
Pages: 122
USD 3950.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 139
USD 3950.00 (Single User License)Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-04-16
Pages: 164
USD 4900.00 (Single User License)Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published: 2026-04-16
Pages: 142
USD 4250.00 (Single User License)Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 119
USD 3950.00 (Single User License)Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 90
USD 2900.00 (Single User License)Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-20
Pages: 90
USD 2900.00 (Single User License)Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-11
Pages: 122
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now